These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16690963)

  • 41. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
    Guidoboni M; Zancai P; Cariati R; Rizzo S; Dal Col J; Pavan A; Gloghini A; Spina M; Cuneo A; Pomponi F; Bononi A; Doglioni C; Maestro R; Carbone A; Boiocchi M; Dolcetti R
    Cancer Res; 2005 Jan; 65(2):587-95. PubMed ID: 15695403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
    Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
    Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.
    Solomon DA; Wang Y; Fox SR; Lambeck TC; Giesting S; Lan Z; Senderowicz AM; Conti CJ; Knudsen ES
    J Biol Chem; 2003 Aug; 278(32):30339-47. PubMed ID: 12746453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.
    Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
    Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH and immunohistochemistry.
    Hui P; Howe JG; Crouch J; Nimmakayalu M; Qumsiyeh MB; Tallini G; Flynn SD; Smith BR
    Leuk Lymphoma; 2003 Aug; 44(8):1385-94. PubMed ID: 12952233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines.
    Kitahara K; Yasui W; Yokozaki H; Semba S; Hamamoto T; Hisatsugu T; Tahara E
    J Exp Ther Oncol; 1996 Jan; 1(1):7-12. PubMed ID: 9414383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas.
    Medeiros LJ; Hai S; Thomazy VA; Estalilla OC; Romaguera J; Luthra R
    Mod Pathol; 2002 May; 15(5):556-64. PubMed ID: 12011261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
    Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
    Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA.
    Thoms HC; Dunlop MG; Stark LA
    Cell Cycle; 2007 Jun; 6(11):1293-7. PubMed ID: 17525529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
    Shishodia S; Amin HM; Lai R; Aggarwal BB
    Biochem Pharmacol; 2005 Sep; 70(5):700-13. PubMed ID: 16023083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.
    Oh SJ; Cho H; Kim S; Noh KH; Song KH; Lee HJ; Woo SR; Kim S; Choi CH; Chung JY; Hewitt SM; Kim JH; Baek S; Lee KM; Yee C; Park HC; Kim TW
    Cancer Res; 2018 May; 78(10):2638-2653. PubMed ID: 29437706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
    Lo RK; Kwong YL
    Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
    Saab R; Bills JL; Miceli AP; Anderson CM; Khoury JD; Fry DW; Navid F; Houghton PJ; Skapek SX
    Mol Cancer Ther; 2006 May; 5(5):1299-308. PubMed ID: 16731763
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma.
    Gladden AB; Woolery R; Aggarwal P; Wasik MA; Diehl JA
    Oncogene; 2006 Feb; 25(7):998-1007. PubMed ID: 16247460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.